Abstract | BACKGROUND: METHODS: In a double-blind, placebo-controlled trial, 57 patients with a history of systemic allergic reactions to honeybee stings and positive diagnostic tests (skin tests, serum specific IgE to honeybee venom) were investigated. Bee venom immunotherapy was started with an ultrarush protocol and patients were randomized to pretreatment with either fexofenadine 180 mg or placebo on days 1, 8, 22, and 50 of the protocol. Local and systemic allergic side-effects were registered. RESULTS: Fifty-four patients completed the study, 28 on fexofenadine and 26 on placebo pretreatment. On day 1, large local reactions were significantly reduced in both extension and duration by fexofenadine pretreatment (P<0.025). Systemic allergic side-effects on the whole were not reduced. However, the symptoms pruritus, urticaria, and angioedema occurred less frequently with fexofenadine (P<0.05). CONCLUSIONS:
|
Authors | A Reimers, Y Hari, U Müller |
Journal | Allergy
(Allergy)
Vol. 55
Issue 5
Pg. 484-8
(May 2000)
ISSN: 0105-4538 [Print] Denmark |
PMID | 10843430
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Allergic Agents
- Bee Venoms
- Terfenadine
- fexofenadine
|
Topics |
- Adolescent
- Adult
- Angioedema
(therapy)
- Anti-Allergic Agents
(therapeutic use)
- Bee Venoms
(adverse effects, therapeutic use)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hypersensitivity, Immediate
(prevention & control)
- Male
- Middle Aged
- Pruritus
(therapy)
- Skin Tests
- Terfenadine
(analogs & derivatives, therapeutic use)
- Urticaria
(therapy)
|